Memantine HCl Clinical Trials

Size	Price	Qty
200mg	USD 147
500mg	USD 247

Clinical Trials

Memantine hydrochloride has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4 across diverse indications, including Alzheimer disease, neurocognitive dysfunction, obsessive-compulsive disorder, neuropathic pain, and autism spectrum disorder. Supported by academic medical centers, university health systems, and pharmaceutical manufacturers such as Allergan and Tata Memorial Centre, these studies encompass recruiting, completed, active, and terminated protocols. Recent efforts include a Phase 3 trial on neurocognitive preservation and a Phase 2 study evaluating Alzheimer disease prevention.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04302870	RECRUITING	Motor Neuron Disease, Amyotrophic Lateral Sclerosis	University of Edinburgh	2020-02-27	PHASE2; PHASE3
NCT07560878	RECRUITING	Major Depression	Mclean Hospital	2026-03-11	EARLY_PHASE1
NCT07470606	NOT_YET_RECRUITING	Brain Tumor	The University of Texas Health Science Center at San Antonio	2026-03	PHASE2
NCT00262470	ACTIVE_NOT_RECRUITING	Tachycardia; Chronic Orthostatic Intolerance	Satish R. Raj	1997-04	PHASE1; PHASE2
NCT06727773	RECRUITING	Breast Cancer; Locally Advanced Breast Cancer; Cognitive Impairment; Cognitive Decline; Cognitive Change; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III	UNC Lineberger Comprehensive Cancer Center	2025-08-19	PHASE2
NCT07505979	NOT_YET_RECRUITING	Brain Metastases From Solid Tumors	National Taiwan University Hospital	2026-04	PHASE2
NCT07164794	NOT_YET_RECRUITING	Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer; Neuroendocrine Prostate Cancer (NEPC)	Bin Xu	2025-11	PHASE2
NCT07531940	NOT_YET_RECRUITING	Down Syndrome; Intellectual Disability	University Hospitals Cleveland Medical Center	2026-06	PHASE1
NCT05045950	RECRUITING	Brain Metastases	Medical College of Wisconsin	2021-11-17	PHASE2
NCT05013892	RECRUITING	Brain Metastases	Massachusetts General Hospital	2022-02-08	PHASE2
NCT07139834	RECRUITING	Major Depressive Disorder (MDD)	Jeffrey Miller	2026-06-01	PHASE1
NCT04539951	RECRUITING	Obsessive-Compulsive Disorder	Shanghai Mental Health Center	2020-09-22	PHASE2
NCT03550391	RECRUITING	Brain Metastases	Canadian Cancer Trials Group	2018-11-22	PHASE3
NCT02144584	ACTIVE_NOT_RECRUITING	Ischemic Stroke; Upper Extremity Weakness	University of Utah	2014-01	EARLY_PHASE1
NCT07248228	RECRUITING	Brain Metastases	Case Comprehensive Cancer Center	2026-07-09	PHASE2
NCT07251023	RECRUITING	Alzheimer Type Dementia	Bigespas LTD	2025-11-20	PHASE3
NCT07504198	NOT_YET_RECRUITING	Peripheral Nerve Disease	Tanta University	2026-03	PHASE2; PHASE3
NCT05063851	ACTIVE_NOT_RECRUITING	Alzheimer Disease	University of Virginia	2021-10-11	PHASE2
NCT06041789	RECRUITING	Osteoporosis	Duke University	2025-02-03	PHASE2
NCT06789757	RECRUITING	Hepatocellular Carcinoma	Inova Health Care Services	2025-02-25	PHASE2
NCT06007846	RECRUITING	Hepatocellular Carcinoma; Cirrhosis	Inova Health Care Services	2023-07-31	PHASE2; PHASE3
NCT04939597	ACTIVE_NOT_RECRUITING	Central Nervous System Carcinoma	Children's Oncology Group	2022-05-10	PHASE3
NCT04804644	RECRUITING	Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8	NRG Oncology	2021-06-08	PHASE3
NCT05664464	RECRUITING	Glioblastoma	University of Zurich	2023-01-01	PHASE1; PHASE2
NCT05796752	ACTIVE_NOT_RECRUITING	Skin-Picking; Trichotillomania (Hair-Pulling Disorder)	University of Chicago	2023-08-02	PHASE2; PHASE3
NCT03527472	COMPLETED	Lupus Erythematosus, Systemic	Vanderbilt University Medical Center	2018-08-23	PHASE2
NCT06275035	RECRUITING	Neurocognitive Dysfunction	Tata Memorial Centre	2024-02-22	PHASE3
NCT06594172	NOT_YET_RECRUITING	Radiation Disease; Cognitive Impairment; Drug Effect	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	2024-09-10	PHASE2
NCT04966546	WITHDRAWN	Chronic Subdural Hematoma	University of New Mexico	2022-06-01	EARLY_PHASE1
NCT03553875	TERMINATED	Autism; Autism Spectrum Disorder; Nonverbal Learning Disability	Massachusetts General Hospital	2018-11-13	PHASE3
NCT05418049	ACTIVE_NOT_RECRUITING	Fragile X Syndrome	Children's Hospital Medical Center, Cincinnati	2022-09-08	PHASE2
NCT06679387	RECRUITING	Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Ain Shams University	2024-10-30	PHASE2
NCT06914310	NOT_YET_RECRUITING	Mild Traumatic Brain Injury; Moderate Traumatic Brain Injury (TBI)	Mansoura University	2025-03-25	PHASE2; PHASE3
NCT07417670	COMPLETED	Alzheimer Disease	Carnot Laboratories	2024-10-04	PHASE4
NCT04789915	RECRUITING	Psychosis; Negative Symptoms With Primary Psychotic Disorder	Bjorn H. Ebdrup	2021-05-26	PHASE1
NCT07351773	COMPLETED	Alzheimer's Disease(AD); Cognitive Dysfunction	Taizhou Second People's Hospital	2025-01-26
NCT04857983	COMPLETED	Schizophrenia; Schizoaffective Disorder	University of California, San Diego	2021-07-06	PHASE2; PHASE3
NCT06501638	COMPLETED	Atrial Premature Beats, Contractions, or Systoles	Shanghai East Hospital	2024-08-29	PHASE2
NCT01430351	TERMINATED	Glioblastoma; Gliosarcoma; Supratentorial Glioblastoma	M.D. Anderson Cancer Center	2011-09-14	PHASE1
NCT03703856	COMPLETED	Alzheimer Disease	University of California, San Diego	2019-01-31	PHASE4
NCT03342443	UNKNOWN	Cognitive Impairment	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2017-12-06	PHASE2; PHASE3
NCT04588246	TERMINATED	Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Breast Neoplasm; Metastatic Malignant Digestive System Neoplasm; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Recurrent Brain Neoplasm; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8	NRG Oncology	2021-08-05	PHASE3
NCT04687566	UNKNOWN	Amphetamine Addiction; Pharmacotherapy	National Cheng-Kung University Hospital	2020-08-11	PHASE2; PHASE3
NCT05430867	UNKNOWN	Treatment; Efficacy; Safety; Alzheimer Disease	First Affiliated Hospital Xi'an Jiaotong University	2022-07-01	PHASE4
NCT06337994	COMPLETED	Treatment of Cognitive Deficits After Traumatic Brain Injury	Assiut University	2024-01-01	PHASE3
NCT05538507	UNKNOWN	Alzheimer Disease; Mild Cognitive Impairment	Peking Union Medical College Hospital	2022-06-01	PHASE2
NCT05834231	UNKNOWN	Cancer	Mansoura University	2023-08	PHASE1; PHASE2
NCT06275035	Recruiting	Neurocognitive Dysfunction	Tata Memorial Centre	2024-02-22	Phase 3
NCT04801342	UNKNOWN	Metastatic Malignant Neoplasm to Brain	National Taiwan University Hospital	2021-04-01	PHASE2
NCT05531383	UNKNOWN	Traumatic Brain Injury	Minia University	2021-11-26
NCT03194906	COMPLETED	Glioma of Brain; Craniopharyngioma; Ependymoma; Germ Cell Tumor	St. Jude Children's Research Hospital	2017-11-07	PHASE2
NCT03954613	UNKNOWN	Alzheimer Disease; Cognitive Change	Neutec Ar-Ge San ve Tic A.Ş	2020-10-15	PHASE4
NCT04117178	COMPLETED	Dementia; Dementia With Lewy Bodies; Dementia in Parkinsons Disease; Dementia Alzheimers; Alzheimer Disease	Zealand University Hospital	2020-02-04	PHASE4
NCT05804279	Completed	Healthy	Hyundai Pharm	2022-12-28	Phase 1
NCT04538066	COMPLETED	Alzheimer Disease	Neurotrope Bioscience, Inc.	2020-08-30	PHASE2
NCT05015595	UNKNOWN	Obsessive-Compulsive Disorder	University of Roma La Sapienza	2021-09-01	PHASE3
NCT04217694	COMPLETED	Malignant Central Nervous System Neoplasm; Primary Central Nervous System Neoplasm	Mayo Clinic	2020-02-17	EARLY_PHASE1
NCT04792645	COMPLETED	Trichotillomania (Hair-Pulling Disorder); Dermatillomania	University of Chicago	2021-06-15	PHASE2
NCT03986424	COMPLETED	Vascular Dementia	Merz Pharmaceuticals GmbH	2018-01-23	PHASE3
NCT04033419	COMPLETED	Cognitive Decline; Chemo-brain	UNC Lineberger Comprehensive Cancer Center	2019-09-25	PHASE2
NCT03858270	UNKNOWN	Parkinson Disease	Wayne State University	2019-04-01	PHASE3
NCT03686774	UNKNOWN	Neuropathic Pain	University Hospital, Clermont-Ferrand	2019-02-15	PHASE2
NCT03779672	COMPLETED	Epileptic Encephalopathy, Childhood-Onset	Kenneth Myers, MD	2019-02-07	PHASE4
NCT05063851	Recruiting	Alzheimer Disease	University of Virginia	2021-10-11	Phase 2
NCT05015595	Unknown status	Obsessive-Compulsive Disorder	University of Roma La Sapienza	2021-09-01	Phase 3
NCT04737967	UNKNOWN	Oncology Pain; Chemotherapy-induced Peripheral Neuropathy	Mendel AI	2021-02-15	PHASE2; PHASE3
NCT04035798	UNKNOWN	Bipolar II Disorder	National Cheng-Kung University Hospital	2019-08-01	PHASE2; PHASE3
NCT02118727	COMPLETED	Amyotrophic Lateral Sclerosis; Frontal Temporal Dementia	University of Kansas Medical Center	2018-11-07	PHASE2
NCT02811627	COMPLETED	Autism Spectrum Disorder	University of Missouri-Columbia	2016-06	EARLY_PHASE1
NCT03860597	COMPLETED	Schizophrenia; Schizo Affective Disorder; Schizoaffective Disorder; Healthy	University of California, San Diego	2018-04-01	PHASE4
NCT02288000	TERMINATED	Alzheimer Disease; Battery	University Hospital, Lille	2016-09-14	PHASE1
NCT03247218	UNKNOWN	Sickle Cell Disease	HaEmek Medical Center, Israel	2018-02-02	PHASE2
NCT03729128	COMPLETED	Stimulants Use Disorder	Tzu-Yun Wang	2018-07-24	PHASE1; PHASE2
NCT02304302	COMPLETED	Down Syndrome; Intellectual Disability	University Hospitals Cleveland Medical Center	2014-10	PHASE2
NCT02630888	UNKNOWN	Bipolar Disorder	University of Sao Paulo	2014-08	PHASE2
NCT04698525	COMPLETED	Migraine Headache	Universidad Autonoma de San Luis Potosí	2019-02-15	PHASE3
NCT02580305	COMPLETED	Alzheimer's Disease	Suven Life Sciences Limited	2015-09	PHASE2
NCT03988803	COMPLETED	Healthy	Boehringer Ingelheim	2019-07-17	PHASE1
NCT04417543	COMPLETED	Epilepsy	Assiut University	2018-10-01	PHASE1
NCT03560245	COMPLETED	Alzheimer Disease	Neurotrope Bioscience, Inc.	2018-06-20	PHASE2
NCT01555697	COMPLETED	Schizophrenia	University of California, San Diego	2014-07	PHASE1; PHASE2
NCT03802162	COMPLETED	Alzheimer's Disease (AD)	Chong Kun Dang Pharmaceutical	2019-02-15	PHASE1
NCT01902004	COMPLETED	Mild Cognitive Impairment (MCI); Depression	University of California, Los Angeles	2013-10	PHASE4
NCT03670095	COMPLETED	Healthy	H. Lundbeck A/S	2018-08-28	PHASE1
NCT03316898	WITHDRAWN	Alzheimer's Disease	Allergan	2018-09-30	PHASE1
NCT03711825	COMPLETED	Alzheimer Disease; Gastric Retention; Healthy	Lyndra Inc.	2018-09-10	EARLY_PHASE1
NCT03168997	UNKNOWN	Alzheimer Disease	Wei Cuibai	2017-07-15	PHASE4
NCT02080364	TERMINATED	Alzheimer's Disease	vTv Therapeutics	2015-04	PHASE3
NCT03038035	UNKNOWN	Alzheimer Disease	National University Hospital, Singapore	2016-12	PHASE2
NCT03569579	COMPLETED	Central Nervous System Diseases	Chong Kun Dang Pharmaceutical	2018-04-16	PHASE1
NCT01972074	COMPLETED	Autism Spectrum Disorder	Massachusetts General Hospital	2015-02-17	PHASE3
NCT02360215	COMPLETED	Cognitive Impairment; Metastatic Malignant Neoplasm in the Brain; Solid Neoplasm	NRG Oncology	2015-07	PHASE3
NCT03468543	TERMINATED	Gastric Retention; Healthy	Lyndra Inc.	2017-07-26	EARLY_PHASE1
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT05102045	COMPLETED	Alzheimer Disease	Istanbul Medipol University Hospital	2016-09-01
NCT01519063	COMPLETED	Alcohol Drinking	Yale University	2012-01	PHASE2
NCT01656187	COMPLETED	Organic Memory Impairment	University of Texas Southwestern Medical Center	2012-01	PHASE4
NCT03043001	UNKNOWN	AOD Effects and Consequences	National Cheng-Kung University Hospital	2014-01-01	PHASE3
NCT03039842	UNKNOWN	Bipolar Disorder II	National Cheng-Kung University Hospital	2013-01-01	PHASE3
NCT02233556	UNKNOWN	Schizophrenia	National Taiwan University Hospital	2014-02
NCT03121820	COMPLETED	Bioequivalence, AUC, Cmax, Pharmacokinetics	Geropharm	2016-10-11	PHASE1
NCT02535611	COMPLETED	Ischemic Stroke; Excitotoxicity; Memantine	Mazandaran University of Medical Sciences	2015-10	PHASE3
NCT02246075	WITHDRAWN	Alzheimer's Disease; Dementia; Cognition	FORUM Pharmaceuticals Inc	2015-07	PHASE2
NCT02234752	TERMINATED	Schizophrenia; Schizoaffective Disorder	Sheppard Pratt Health System	2014-09	PHASE2
NCT02553928	COMPLETED	Alzheimer Dementia (AD)	H. Lundbeck A/S	2015-10	PHASE4
NCT02001103	UNKNOWN	Schizophrenia	National Taiwan University Hospital	2014-01	PHASE3
NCT01585168	COMPLETED	Healthy	Yale University	2011-12	PHASE2
NCT02240589	COMPLETED	Traumatic Brain Injury	Indiana University	2014-12
NCT01409694	COMPLETED	Alzheimer Disease	University Hospital, Angers	2011-09	PHASE3
NCT02466191	COMPLETED	Pendular Nystagmus; Oculopalatal Tremor	Hospices Civils de Lyon	2015-06	PHASE4
NCT00956085	COMPLETED	Obsessive-Compulsive Disorder	New York State Psychiatric Institute	2009-08	PHASE2
NCT01372449	COMPLETED	Autism Spectrum Disorder	Evdokia Anagnostou	2011-12	PHASE2
NCT01677754	COMPLETED	Alzheimer's Disease	Hoffmann-La Roche	2012-10-24	PHASE2
NCT02136823	UNKNOWN	Chronic Spinal Cord Injury	Shirley Ryan AbilityLab	2009-06
NCT01844427	WITHDRAWN	ADHD; Executive Function Deficits (EFD's)	Massachusetts General Hospital	2013-07
NCT01032759	TERMINATED	Pain	Duke University	2009-12	PHASE4
NCT01461174	COMPLETED	Healthy	Qualissima	2011-11	PHASE1
NCT01849042	UNKNOWN	Alzheimer's Disease; Dementia	Konkuk University Medical Center	2013-01	PHASE4
NCT01333865	COMPLETED	Autism Spectrum Disorders	Massachusetts General Hospital	2010-01	PHASE4
NCT02570581	COMPLETED	Healthy	Centre Hospitalier Universitaire de Nice	2014-06	PHASE1
NCT01602185	COMPLETED	Neuropathic Pain	University Hospital, Clermont-Ferrand	2012-05	PHASE2
NCT01054599	COMPLETED	Epilepsy	American Academy of Neurology	2009-01
NCT02467556	COMPLETED	CRPS	Helsinki University Central Hospital	2011-03	PHASE4
NCT02001584	COMPLETED	Healthy Volunteers;; Obese, Otherwise Healthy Volunteers	Gedeon Richter Plc.		PHASE1
NCT01260467	TERMINATED	Glioblastoma	University of Rochester	2010-11	PHASE2
NCT01535040	COMPLETED	Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer; Tobacco Use Disorder	Wake Forest University Health Sciences	2012-08-01	PHASE2
NCT01592773	TERMINATED	Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Forest Laboratories	2012-10	PHASE2
NCT00703430	UNKNOWN	Alzheimer's Disease	Peking University	2008-03
NCT01536314	COMPLETED	Neuropathic Pain	University Hospital, Clermont-Ferrand	2012-02	PHASE3
NCT01592747	COMPLETED	Autistic Disorder; Autism; Asperger's Disorder; Asperger Syndrome; Autism Spectrum Disorders; Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)	Forest Laboratories	2012-09	PHASE2
NCT01592786	COMPLETED	Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Forest Laboratories	2012-06	PHASE2
NCT01533493	COMPLETED	Attention Deficit Hyperactivity Disorder (ADHD); Executive Function Deficits (EFD)	Massachusetts General Hospital	2012-05
NCT01744444	COMPLETED	Pendular Nystagmus Patients With Multiple Sclerosis	Hospices Civils de Lyon	2012-11	PHASE2
NCT01052662	COMPLETED	Opioid Dependence	University of Massachusetts, Worcester	2009-10	PHASE2; PHASE3
NCT01626391	TERMINATED	Alzheimer's Disease	TauRx Therapeutics Ltd	2012-09	PHASE2
NCT01999894	COMPLETED	Autism; Pediatric Autism	Forest Laboratories	2009-11	PHASE2
NCT00545974	COMPLETED	Frontal Lobe Dementia; Frontotemporal Lobe Dementia; Semantic Dementia	University of California, San Francisco	2007-10	PHASE4
NCT01188148	COMPLETED	Bipolar Disorders	National Cheng-Kung University Hospital	2009-08	PHASE2; PHASE3
NCT01653457	UNKNOWN	Fibromyalgia	Aragon Institute of Health Sciences	2012-09	PHASE3
NCT00476008	COMPLETED	Alzheimer's Disease	Florida Atlantic University	2007-07	PHASE4
NCT00584948	COMPLETED	Fragile X-Associated Tremor/Ataxia Syndrome; Fragile X Premutation Carriers	University of California, Davis	2007-09
NCT00235716	COMPLETED	Alzheimer's Disease	US Department of Veterans Affairs	2007-08	PHASE3
NCT00872898	COMPLETED	Autism	Forest Laboratories	2009-04	PHASE2
NCT01458470	COMPLETED	Huntington Disease	University of British Columbia	2011-09	PHASE2
NCT00594737	COMPLETED	Frontotemporal Dementia	Tiffany Chow, MD	2007-10	PHASE3
NCT00880685	COMPLETED	Kleptomania	University of Chicago	2009-03	PHASE2
NCT01392287	COMPLETED	Major Depressive Disorder	Mclean Hospital	2010-05	PHASE1
NCT00866060	UNKNOWN	Moderate to Severe Alzheimer's Disease	King's College London	2008-02	PHASE4
NCT00986115	WITHDRAWN	Epilepsy	University of California, Davis	2010-07
NCT00551161	COMPLETED	Alzheimer Disease	Northwell Health	2007-08	PHASE4
NCT00585169	COMPLETED	Pathological Gambling	Yale University	2007-12	PHASE2
NCT00344682	COMPLETED	Depressive Disorder	University of Massachusetts, Worcester	2006-06	PHASE4
NCT00120874	COMPLETED	Alzheimer's Disease	NYU Langone Health	2006-08	PHASE4
NCT00933608	COMPLETED	Alzheimer's Disease	NYU Langone Health	2009-07	PHASE4
NCT00980408	COMPLETED	Healthy Individuals	University Hospital, Bonn	2008-06
NCT01261741	COMPLETED	Memory Disorder; Retention Disorder, Cognitive; Subjective Cognitive Impairment; Memory, Concentration or Attention Problems	Merz Pharmaceuticals GmbH	2010-11	PHASE2
NCT00476242	COMPLETED	Opioid Dependence; Heroin Dependence	New York State Psychiatric Institute	2008-06	PHASE2; PHASE3
NCT01112683	COMPLETED	Down Syndrome	University of Colorado, Denver	2008-07	PHASE4
NCT01041313	UNKNOWN	Pain, Post-operative	University of Washington	2010-01	PHASE4
NCT01038128	COMPLETED	Bulimia Nervosa; Body Dysmorphic Disorder	Mclean Hospital	2009-12
NCT00630955	COMPLETED	Alcohol Drinking	Yale University	2006-06	PHASE2
NCT00566852	COMPLETED	Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific	Radiation Therapy Oncology Group	2008-03	PHASE3
NCT01074619	COMPLETED	Multiple Sclerosis	University Hospital, Caen	2005-09	PHASE3
NCT01189214	COMPLETED	Substance Abuse	National Cheng-Kung University Hospital	2009-03	PHASE3
NCT00305578	COMPLETED	Bipolar Depression	Indiana University	2005-08	PHASE4
NCT00409721	COMPLETED	Amyotrophic Lateral Sclerosis	University of Alberta	2007-03	PHASE2
NCT00462228	TERMINATED	Traumatic Brain Injury	University of Missouri-Columbia	2007-04	PHASE4
NCT00800709	COMPLETED	Alzheimer's Disease	Shanghai Mental Health Center	2008-07	PHASE4
NCT01108029	COMPLETED	Parkinson's Disease; Gait Disorders, Neurologic	University Hospital, Lille	2009-10	PHASE4
NCT00830375	COMPLETED	Compulsive Buying	University of Minnesota	2008-12-01	PHASE2
NCT00857233	TERMINATED	Alzheimer's Disease	H. Lundbeck A/S	2004-06	PHASE3
NCT01078844	TERMINATED	Autism; Asperger's Disorder; Pervasive Developmental Disorder NOS	Johns Hopkins University	2010-02
NCT00411398	COMPLETED	General Anxiety Disorder, Social Anxiety Disorder	State University of New York - Upstate Medical University	2006-12	PHASE3
NCT00857649	TERMINATED	Alzheimer's Disease	H. Lundbeck A/S	2003-12	PHASE3
NCT01876823	COMPLETED	Mild Cognitive Impairment; Major Depressive Disorder; Alzheimer's Disease	New York State Psychiatric Institute	2006-04	PHASE2; PHASE3
NCT00401167	COMPLETED	Alzheimer's Disease	Sunnybrook Health Sciences Centre	2006-11	PHASE4
NCT00242632	COMPLETED	Dementia	Stanford University	2004-06
NCT00586066	COMPLETED	Bipolar Disorder	Massachusetts General Hospital	2005-11	PHASE4
NCT00804271	COMPLETED	Alzheimer's Disease	Merz Pharmaceuticals GmbH	2008-12	PHASE3
NCT00988663	WITHDRAWN	Major Depressive Disorder	Jerrry L Lewis	2009-11
NCT01025466	COMPLETED	Alzheimer's Disease	Inha University Hospital	2008-12	PHASE4
NCT00652457	COMPLETED	Huntington's Disease	Jody Corey-Bloom, MD, PhD	2004-11-23	PHASE4
NCT00586573	COMPLETED	ADHD	Massachusetts General Hospital	2007-03	PHASE4
NCT00768261	COMPLETED	Dementia	Washington University School of Medicine	2004-11	PHASE4
NCT01020331	COMPLETED	Amyotrophic Lateral Sclerosis	Phoenix Neurological Associates, LTD	2005-06	PHASE2
NCT00371059	COMPLETED	DEMENTIA	East Kent Hospitals University NHS Foundation Trust	2007-09	PHASE4
NCT00255086	COMPLETED	Alzheimer Disease	Stanford University	2005-05	PHASE3
NCT00183729	COMPLETED	Depression	Eric Lenze	2005-08	PHASE4
NCT00928954	COMPLETED	Nystagmus	Case Western Reserve University	2005-02
NCT00649220	TERMINATED	Alzheimer's Disease	Merz Pharmaceuticals GmbH	2008-07	PHASE4
NCT00136786	COMPLETED	Tobacco Use Disorder	New York State Psychiatric Institute	2006-12	PHASE1
NCT00136747	COMPLETED	Tobacco Use Disorder	New York State Psychiatric Institute	2004-01	PHASE1
NCT00829816	COMPLETED	Alzheimer's Disease	Medivation, Inc.	2008-12	PHASE1
NCT00630500	COMPLETED	Dementia Associated With Parkinson's Disease; Dementia With Lewy Bodies	Helse Stavanger HF	2006-02	PHASE2
NCT00862940	COMPLETED	Alzheimer's Disease	H. Lundbeck A/S	2005-09	PHASE4
NCT00646204	COMPLETED	Parkinson's Disease	Baylor College of Medicine	2006-04	PHASE4
NCT00638027	COMPLETED	Multiple Sclerosis	University of Rochester	2006-07	PHASE4
NCT00300716	COMPLETED	Multiple Sclerosis; Cognition Disorders	Oregon Health and Science University	2004-04	PHASE2; PHASE3
NCT00439699	COMPLETED	Essential Tremor	VA Greater Los Angeles Healthcare System	2007-02	PHASE4
NCT00624026	COMPLETED	Alzheimer's Disease	Merz Pharmaceuticals GmbH	2007-11	PHASE3
NCT00855686	COMPLETED	Parkinson's Disease Dementia; Dementia With Lewy Bodies	H. Lundbeck A/S	2007-01	PHASE4
NCT00469456	COMPLETED	Alzheimer's Disease	Forest Laboratories	2007-04	PHASE4
NCT01921972	COMPLETED	Alzheimer's Disease	Charite University, Berlin, Germany	2004-11	PHASE4
NCT00294554	COMPLETED	Parkinson's Disease; Cognitive Impairment; Dementia	Johns Hopkins University	2006-04
NCT00125515	COMPLETED	Opioid Dependence	New York State Psychiatric Institute	2005-06	PHASE2
NCT00505167	COMPLETED	Dementia, Alzheimer Type	Hospital Miguel Servet	2007-07	PHASE4
NCT00264238	COMPLETED	Obsessive-Compulsive Disorder	Stanford University	2006-01	PHASE1; PHASE2
NCT00353665	COMPLETED	Amyotrophic Lateral Sclerosis	University of Lisbon	2005-07	PHASE2; PHASE3
NCT00148590	TERMINATED	Schizophrenia	M. Schaefer, MD	2005-11	PHASE3
NCT00148616	TERMINATED	Chronic Schizophrenia	M. Schaefer, MD	2004-04	PHASE3
NCT00638833	TERMINATED	Multiple Sclerosis	Clinica Universidad de Navarra, Universidad de Navarra	2007-09	PHASE2
NCT00757978	COMPLETED	Schizophrenia	Hospital de Clinicas de Porto Alegre	2006-01	PHASE4
NCT00674219	COMPLETED	Obsessive-Compulsive Disorder; Generalized Anxiety Disorder	University of California, Los Angeles	2005-05	PHASE3
NCT00640198	COMPLETED	Aphasia; Stroke	Gabinete Berthier y Martínez	2005-03	PHASE4
NCT00334906	COMPLETED	Alzheimer's Disease	Forest Laboratories	2005-07	PHASE4
NCT00322153	COMPLETED	Dementia of the Alzheimer's Type	Forest Laboratories	2005-06	PHASE3
NCT00315666	COMPLETED	Tension-Type Headache	Danish Headache Center	2006-05	PHASE3
NCT00134901	COMPLETED	Cocaine-Related Disorders	New York State Psychiatric Institute	2003-03	PHASE2
NCT00181298	COMPLETED	Systemic Lupus Erythematosus	Johns Hopkins University	2006-03
NCT00283309	TERMINATED	Mood; Memory Deficit	University of Texas Southwestern Medical Center	2005-11	PHASE4
NCT02258828	COMPLETED	PTSD	Sriram Ramaswamy	2005-07	PHASE4
NCT00168350	COMPLETED	Open-Angle Glaucoma	Allergan	2000-03	PHASE3
NCT00097916	COMPLETED	Alzheimer's Disease	Forest Laboratories	2004-09	PHASE3
NCT00186498	COMPLETED	Depressive Disorder, Major	Stanford University	2004-02
NCT00141882	COMPLETED	Open-Angle Glaucoma	Allergan	1999-03	PHASE3
NCT00246415	COMPLETED	Alcohol Dependence (Primary Condition); Alcohol Abuse	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	2002-11	PHASE2
NCT00106405	COMPLETED	Bipolar Disorder	Forest Laboratories	2005-02	PHASE2
NCT00187525	COMPLETED	Frontotemporal Lobar Degeneration	University of California, San Francisco	2004-05	PHASE4
NCT00097942	COMPLETED	Schizophrenia	Forest Laboratories	2004-08	PHASE2
NCT00234637	COMPLETED	Alzheimer's Disease	Novartis	2003-11	PHASE4
NCT00280774	COMPLETED	Physiological Effects of Drugs	University of Texas Southwestern Medical Center	2006-03	PHASE4
NCT00000867	COMPLETED	AIDS Dementia Complex; HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	1996-12	PHASE2
NCT01196065	COMPLETED	Healthy Volunteer	Hoffmann-La Roche	2010-09	PHASE1
NCT00375778	COMPLETED	Parkinson's Disease	University of Aarhus	2005-04
NCT00330655	COMPLETED	Binge Eating Disorder	Mclean Hospital	2006-05	PHASE4
NCT00305903	COMPLETED	Alzheimer's Disease	Novartis	2006-03	PHASE4
NCT00040261	COMPLETED	Depression	National Institute of Mental Health (NIMH)	2002-06	PHASE3
NCT00368862	COMPLETED	Alcoholism; Depression	Finnish Institute for Health and Welfare	2005-12	PHASE4
NCT00196703	UNKNOWN	Aphasia; Stroke	Gabinete Berthier y Martínez	2005-03	PHASE4
NCT00240760	UNKNOWN	Down's Syndrome; Dementia; Learning Disabilities	King's College London	2005-10
NCT00200538	COMPLETED	Dementia	Nantes University Hospital	2005-09	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-04)

Check the Memantine HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Memantine hydrochloride acts as an N-methyl-D-aspartate (NMDA) receptor antagonist, binding to the receptor channel to block pathological glutamate-mediated calcium influx and attenuate downstream excitotoxic signaling while additionally inhibiting cytochrome P450 enzymes CYP2B6 and CYP2D6. This receptor blockade mitigates glutamate-induced neuronal cell death and neurotoxicity, thereby providing clinical utility in managing neurocognitive dysfunction, Alzheimer disease, and chemotherapy-induced cognitive decline or neuropathic pain.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).